$GHSI
Guardion Health Sciences Inc Stock $ghsi

$ghsi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018930 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$72.92K	$3.000M	$3.186M
YoY Change	-97.39%	-5.84%	33.59%
Cost Of Revenue	$36.57K	$1.821M	$1.850M
YoY Change	-97.63%	-1.61%	43.65%
Gross Profit	$36.35K	$1.179M	$1.335M
YoY Change	-97.09%	-11.71%	21.78%
Gross Profit Margin	49.85%	39.3%	41.92%
Selling, General & Admin	$1.404M	$2.197M	$2.737M
YoY Change	-35.74%	-19.73%	-25.75%
% of Gross Profit	3862.35%	186.31%	204.94%
Research & Development		$3.168K	$62.73K
YoY Change		-94.95%	837.73%
% of Gross Profit		0.27%	4.7%
Depreciation & Amortization	$4.570K	$4.790K	$4.790K
YoY Change	-5.38%	0.0%	-98.49%
% of Gross Profit	12.57%	0.41%	0.36%
Operating Expenses	$1.418M	$2.733M	$2.799M
YoY Change	-37.32%	-2.38%	-24.18%
Operating Profit	-$1.381M	-$1.554M	-$1.464M
YoY Change	36.41%	6.13%	-43.6%
Interest Expense	-$751.7K	-$3.193M	$1.997M
YoY Change	-886.79%	-259.88%	127919.23%
% of Operating Profit
Other Income/Expense, Net	-$751.7K	-$3.193M	$1.997M
YoY Change	370.5%	-259.88%	-174.49%
Pretax Income	-$2.133M	-$4.747M	$533.1K
YoY Change	81.94%	-990.42%	-120.36%
Income Tax
% Of Pretax Income
Net Earnings	$10.32M	-$4.747M	$533.1K
YoY Change	-980.61%	-990.42%	-120.36%
Net Earnings / Revenue	14158.82%	-158.24%	16.73%
Basic Earnings Per Share	$8.04	-$3.71	$0.42
Diluted Earnings Per Share	$7.96	-$3.71	$0.42
COMMON SHARES
Basic Shares Outstanding	1.284M shares	1.284M shares	1.267M shares
Diluted Shares Outstanding	1.298M shares	1.280M shares	1.267M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.82M	$5.605M	$8.775M
YoY Change	77.09%	-36.12%	-47.86%
Cash & Equivalents	$14.82M	$5.605M	$8.775M
Short-Term Investments
Other Short-Term Assets	$378.9K	$539.2K	$590.7K
YoY Change	-62.11%	-8.72%	-17.69%
Inventory	$77.80K	$2.134M	$3.061M
Prepaid Expenses
Receivables	$12.73K	$2.103M	$1.947M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.29M	$10.38M	$14.37M
YoY Change	13.86%	-27.77%	-30.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.654K	$25.09K	$45.73K
YoY Change	-84.54%	-45.14%	-51.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.654K	$25.09K	$45.73K
YoY Change	-84.54%	-45.14%	-99.59%
TOTAL ASSETS
Total Short-Term Assets	$15.29M	$10.38M	$14.37M
Total Long-Term Assets	$6.654K	$25.09K	$45.73K
Total Assets	$15.30M	$10.41M	$14.42M
YoY Change	13.54%	-27.82%	-54.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$113.4K	$413.3K	$888.6K
YoY Change	-88.49%	-53.49%	-22.49%
Accrued Expenses	$796.6K	$857.8K	$508.7K
YoY Change	76.04%	68.62%	-25.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$917.3K	$1.271M	$2.178M
YoY Change	-54.05%	-41.64%	19.25%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$631.3K	$5.722M	$3.759M
YoY Change	-85.11%	52.2%
Total Long-Term Liabilities	$631.3K	$5.722M	$3.759M
YoY Change	-85.11%	52.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$917.3K	$1.271M	$2.178M
Total Long-Term Liabilities	$631.3K	$5.722M	$3.759M
Total Liabilities	$1.549M	$6.993M	$5.937M
YoY Change	-75.16%	17.78%	225.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$87.99M	-$98.31M	-$93.19M
YoY Change	-6.76%	5.5%	10.81%
Common Stock	$1.284K	$1.284K	$1.267K
YoY Change	1.34%	1.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.75M	$3.414M	$8.482M
YoY Change
Total Liabilities & Shareholders Equity	$15.30M	$10.41M	$14.42M
YoY Change	13.54%	-27.82%	-54.4%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$10.32M	-$4.747M	$533.1K
YoY Change	-980.61%	-990.42%	-120.36%
Depreciation, Depletion And Amortization	$4.570K	$4.790K	$4.790K
YoY Change	-5.38%	0.0%	-98.49%
Cash From Operating Activities	-$1.080M	-$754.6K	-$1.879M
YoY Change	165.72%	-59.84%	-15.6%
INVESTING ACTIVITIES
Capital Expenditures			$1.654K
YoY Change			-168.92%
Acquisitions
YoY Change
Other Investing Activities	$16.25M		$0.00
YoY Change			-100.0%
Cash From Investing Activities	$16.25M		-$1.654K
YoY Change	-759445.79%		-99.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.952M		-$5.250M
YoY Change			-152.66%
NET CHANGE
Cash From Operating Activities	-1.080M	-$754.6K	-$1.879M
Cash From Investing Activities	16.25M		-$1.654K
Cash From Financing Activities	-5.952M		-$5.250M
Net Change In Cash	9.218M	-$754.6K	-$7.131M
YoY Change	-2355.72%	-89.42%	-1065.52%
FREE CASH FLOW
Cash From Operating Activities	-$1.080M	-$754.6K	-$1.879M
Capital Expenditures			$1.654K
Free Cash Flow		-$754.6K	-$1.881M
YoY Change		-59.88%	-15.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2024Q1	GHSI	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Assets Current AssetsCurrent	10381782	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11884932	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25089	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33245	usd
CY2024Q1	us-gaap	Assets Assets	10406871	usd
CY2023Q4	us-gaap	Assets Assets	11918177	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	413294	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	614122	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	857805	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	704912	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1271099	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1319034	usd
CY2024Q1	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	5721688	usd
CY2023Q4	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	2453100	usd
CY2024Q1	us-gaap	Liabilities Liabilities	6992787	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3772134	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1284156	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1284156	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1275238	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1275238	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1284	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1275	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101725811	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101711035	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98313011	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93566267	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3414084	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8146043	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10406871	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11918177	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2999645	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3185689	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1820645	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1850387	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	1179000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1335302	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3168	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62734	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	361908	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	598655	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1834669	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2050252	usd
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	529690	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	87668	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3366	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2732801	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2799309	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1553801	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1464007	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3268588	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1898100	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	75645	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	98998	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3192943	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1997098	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4746744	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.71
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.71
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1280306	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1280306	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1267340	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1267340	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8146043	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12615	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	2170	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4746744	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3414084	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25182	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	5329	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8481524	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8481524	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4746744	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4790	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4792	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3366	usd
CY2024Q1	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	12615	usd
CY2023Q1	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	25182	usd
CY2024Q1	GHSI	Fair Value Of Vested Restricted Common Stock FairValueOfVestedRestrictedCommonStock	2170	usd
CY2023Q1	GHSI	Fair Value Of Vested Restricted Common Stock FairValueOfVestedRestrictedCommonStock	5329	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3268588	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1898100	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-171069	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22393	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-542899	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-58501	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-34571	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-97235	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-200828	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-629483	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3807	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	152893	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-49557	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-754611	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1879210	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1654	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1654	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	5250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5250000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-754611	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7130864	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6359646	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15905490	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5605035	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8774626	usd
CY2024Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	17200000	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50
CY2023Q1	GHSI	Minimum Closing Bid Price Value MinimumClosingBidPriceValue	1.00
CY2023Q1	GHSI	Minimum Closing Bid Price Value MinimumClosingBidPriceValue	1.00
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4746744	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1553801	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-754611	usd
CY2024Q1	us-gaap	Cash Cash	5605035	usd
CY2024Q1	GHSI	Working Capital WorkingCapital	9110684	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_ziXTGdn931rh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zvo5lJmcSQxi">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1840	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2999645	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3185689	usd
CY2024Q1	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1509600	usd
CY2023Q1	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1937000	usd
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	337364	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	479866	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zOi1wiKCMq93" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zg8h2T7KnARk">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue. </i>During the three months ended March 31, 2024, the Company had two customers that accounted for an aggregate of <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zAE7mLb3e99k" title="Concentration risk percentage">72</span>% of total revenue. The largest customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargestCustomerMember_zz9RSxeceEGk" title="Concentration risk percentage">46</span>% of the Company’s total revenue, the second largest customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondLargestCustomerMember_ztI9DeNKQSgj" title="Concentration risk percentage">26</span>% of the Company’s total revenue. During the three months ended March 31, 2023, the Company had three customers that accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zjQgCCIqWPKg" title="Concentration risk percentage">80</span>% of the Company’s total revenue. The largest customer accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargestCustomerMember_zbfycKRlJHV7" title="Concentration risk percentage">59</span>% of the Company’s total revenue, the second largest customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_zWZGFsdtZz14" title="Concentration risk percentage">11</span>% of the Company’s total revenue and the third largest customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdLargestCustomersMember_zaLY3Wxqcg56" title="Concentration risk percentage">10</span>% of the Company’s revenue. No other customer accounted for more than <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zoCL47o2jws1" title="Concentration risk percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zpBS9feRLcvh" title="Concentration risk percentage">10</span></span>% of revenue during the three months ended March 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts receivable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2024<span style="background-color: white">, the Company had accounts receivable from two customers which comprised approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zJ4fkW0sjasb" title="Concentration Risk, Percentage">81</span>% of its accounts receivable. The largest customer accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargestCustomerMember_zR5uQD0e9An9" title="Concentration Risk, Percentage">61</span>% of the accounts receivable total and the other customer accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__us-gaap--OtherCustomerMember_zODmrzDrga15" title="Concentration Risk, Percentage">20</span>%. As of </span>December 31, 2023<span style="background-color: white">, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomersMember_zc9MAUGQCawg" title="Concentration risk percentage">57</span>% of its accounts receivable and one customer that accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zRm1EsfNjtqc" title="Concentration Risk, Percentage">18</span>% of its accounts receivable. No other customer accounted for more than <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zmG6tBMfnZma" title="Concentration risk percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zVYoI71n7s6l" title="Concentration risk percentage">10</span></span>% of accounts receivable as of </span>March 31, 2024 <span style="background-color: white">and December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Purchases from vendors</i>. During the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">three months ended March 31, 2024 and 2023<span style="background-color: white">, the Company utilized one manufacturer for most of its production and packaging of its dietary supplement products. Total purchases from this manufacturer accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zPzEjncUTuKk">40</span>% of all purchases during the three months ended </span>March 31, 2024 <span style="background-color: white">and approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zk9tROKb9pr9">49</span>% of all purchases during the three months ended March 31, 2023. The Company utilized a firm to manage and handle media and advertising of its dietary supplement products. Total purchases from this vendor accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_z2C9aI2FIya1">10</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zMMVjhdnCwQl">13</span>% of all purchases during the three months ended </span>March 31, 2024 and 2023, respectively. No other vendors accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoOtherVendorMember_zhjG6S9Aa3P8"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoOtherVendorMember_zxC9Su4vv9y1">10</span></span>% of purchases during the three months ended March 31, 2024 and 2023<span style="background-color: white">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts payable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2024<span style="background-color: white">, two vendors accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoVendorsMember_zhmEDXTEQyxa" title="Concentration Risk, Percentage">82</span>% of total accounts payable. One vendor accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zPqm7kZ9YT48" title="Concentration Risk, Percentage">72</span>% and a second vendor accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondVendorMember_z1L2FdELkpxk" title="Concentration Risk, Percentage">10</span>% of the accounts payable at March 31, 2024. As of </span>December 31, 2023, <span style="background-color: white">one vendor accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zvR6jKe8zvx8" title="Concentration Risk, Percentage">91</span>% of the total accounts payable. No other vendor accounted for more than <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoOtherVendorMember_zgNvPtlnv8Xb" title="Concentration Risk, Percentage"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoOtherVendorMember_zKrzAyOBwiJg" title="Concentration Risk, Percentage">10</span></span>% of accounts payable as of </span>March 31, 2024 <span style="background-color: white">and December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash and cash equivalents.</i> Cash and cash equivalents consist of funds deposited with BMO Harris Bank(“BMO”), a major, established, high quality financial institution in short-term (original maturity of generally 60 days or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests solely in high quality U.S. government issued securities. As of March 31, 2024, $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331_z2jtO5XgF299" title="Cash">5,605,035</span> included in cash and cash equivalents was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance Corporation (the “FDIC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zON3WBg8dABk" title="Cash FDIC insured amount">250,000</span> and $<span id="xdx_908_ecustom--CashSIPCInsuredAmount_iI_c20240331_zZXVQHMtUDqd" title="Cash SIPC insured amount">500,000</span>, respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced any losses to date resulting from this policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5605035	usd
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	GHSI	Cash Sipc Insured Amount CashSIPCInsuredAmount	500000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	757348	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1539827	shares
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	5721688	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2453100	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2453100	usd
CY2024Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3268588	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	5721688	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	35405	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	35404	usd
CY2024Q1	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	2098808	usd
CY2023Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	2641708	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2134213	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2677112	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	5721688	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2453100	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	5250000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4750000	usd
CY2023Q1	GHSI	Proceeds From Issuance Of Private Placement Additional ProceedsFromIssuanceOfPrivatePlacementAdditional	500000	usd
CY2023Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.05	pure
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1284156	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1284156	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1275238	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1275238	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	736438	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20577	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	77.72
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20577	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	77.72
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M20D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13153	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	116.19
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M3D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20577	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13153	shares
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12615	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25182	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7424	shares
CY2024Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	123000	usd
CY2024Q1	GHSI	Share Based Compensation Amortized Period ShareBasedCompensationAmortizedPeriod	P4Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	9.02
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	34138	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	0	shares
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5700000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-018930-index-headers.html	Edgar Link	pending
0001493152-24-018930-index.html	Edgar Link	pending
0001493152-24-018930.txt	Edgar Link	pending
0001493152-24-018930-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
ghsi-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
ghsi-20240331_def.xml	Edgar Link	unprocessable
ghsi-20240331_lab.xml	Edgar Link	unprocessable
ghsi-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ghsi-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GHSI
Guardion Health Sciences Inc Stock $ghsi

2024 Q2 Form 10-Q Financial Statement

#000149315224018930 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI Guardion Health Sciences Inc Stock $ghsi

2024 Q2 Form 10-Q Financial Statement

#000149315224018930 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI
Guardion Health Sciences Inc Stock $ghsi